Miscellaneous
For the estimated 2.8 million Americans suffering from treatment-resistant depression (TRD), the arrival of esketamine nasal spray in 2019 couldn’t come soon enough. The FDA’s decision to approve the drug, the first ketamine-based antidepressant, was the latest chapter in ketamine’s journey from anesthetic to club drug to antidepressant. It was also the result of two decades of research, including by Dennis S. Charney*, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai, and James Murrough, MD, PhD, Director of the Depression and Anxiety Center for Discovery and Treatment. On Road to Resilience, Dr. Murrough explains about how ketamine differs from existing antidepressants and shares actionable insights into the neurobiology of depression. Dr. James Murrough, MD, PhD, is Associate Professor of Psychiatry and Neuroscience and Director of the Depression and Anxiety Center for Discovery and Treatment at the Icahn School of Medicine at Mount Sinai.Links:Five Things to Know About Esketamine (with Dr. Murrough)Depression and Anxiety Center for Discovery and Treatment (DAC)Follow the Depression and Anxiety Center on TwitterDepartment of Psychiatry at the Icahn School of MedicineFollow Mount Sinai Psychiatry on TwitterFor photos, links, and transcripts of all our episodes, visit www.mountsinai.org/rtr*Dr. Charney is a named co-inventor on several issued and pending patents filed by Mount Sinai related to ketamine and pharmacologic therapy for treatment-resistant depression, suicidal ideation, and other disorders. Patents have been licensed by Mount Sinai to Janssen Pharmaceuticals, Inc. (manufacturer of Spravato) and the medical school, and Dr. Charney as a faculty co-inventor, has received and will receive future payments from Janssen. Dr. Murrough has no financial interests related to ketamine.